Please assess the completion status of the following clinical trial:

Trial Title: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 5 years to 65 years of age.~* Clinical diagnosis of MPS II (based on evidence of hepatosplenomegaly, dysostosis multiplex by X-ray, valvular heart disease, or obstructive airway disease) IDS deficiency confirmed by gene sequencing.~Exclusion Criteria:~* Known to be unresponsive to ERT~* Neutralizing antibodies to AAV 2/6~* Serious intercurrent illness or clinically significant organic disease (unless secondary to MPS II)~* Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or hepatitis C or HIV 1/2~* Lack of tolerance to idursulfase treatment with significant IARs or occurrence of anaphylaxis~* Markers of hepatic dysfunction~* Creatinine ≥ 1.5 mg/dL~* Contraindication to the use of corticosteroids for immunosuppression~* Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use (topical treatment allowed)~* Participation in prior investigational drug or medical device study within the previous 3 months~* Prior treatment with a gene therapy product~* Elevated or abnormal circulating α-fetoprotein (AFP)~* Weight \< 20 kg at Screening Visit

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 SB-913 Starting Dose 5.00E+12 vg/kg (Type: EXPERIMENTAL): A single dose of each of the three components of SB-913 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
- Cohort 2 SB-913 at Next Ascending Dose 1.00E+13 vg/kg (Type: EXPERIMENTAL): A single dose of each of the three components of SB-913 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
- Cohort 3 SB-913 at Next Ascending Dose 5.00E+13 vg/kg (Type: EXPERIMENTAL): A single dose of each of the three components of SB-913 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).